CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 82 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-23 | Rubin Eyal Sr. VP and CFO | Grant or award | +99,010 | 669,010 | ||
| 2024-09-23 | Naos Yaron Sr. VP, Operations | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-04-01 | Bashan Dror PRESIDENT AND CEO | Grant or award | +263,960 | 2,149,418 | ||
| 2023-10-19 | Bashan Dror PRESIDENT AND CEO | Purchase | +48,387 | $1.40 | $68K | 116,387 |
| 2023-10-19 | Bashan Dror PRESIDENT AND CEO | Purchase | +16,129 | $1.41 | $23K | 132,516 |
| 2023-09-29 | Boudes Pol F Director | Grant or award · Stock Options (Right to Buy) | +61,676 | 61,676 | ||
| 2023-09-29 | Melincoff Gwen A Director | Grant or award · Stock Options (Right to Buy) | +61,676 | 61,676 | ||
| 2023-09-29 | Bar-Shalev Amos Director | Grant or award · Stock Options (Right to Buy) | +61,676 | 61,676 | ||
| 2023-09-29 | Schwartz Aharon Director | Grant or award · Stock Option (Right to Buy) | +61,676 | 61,676 | ||
| 2023-09-29 | Ben Zvi Shmuel Director | Grant or award · Stock Option (Right to Buy) | +61,676 | 61,676 | ||
| 2023-09-14 | Forster Eliot Director | Grant or award · Stock Options (Right to Buy) | +85,715 | 85,715 | ||
| 2023-08-15 | Bashan Dror President and CEO | Grant or award | +800,000 | 1,885,458 | ||
| 2023-08-15 | Rubin Eyal Sr. VP and CFO | Grant or award | +201,903 | 570,000 | ||
| 2023-08-15 | Hayon Yael VP, Research & Development | Grant or award | +35,115 | 35,115 | ||
| 2023-08-15 | Hayon Yael VP, Research & Development | Grant or award · Stock Options (Right to Buy) | +35,115 | 35,115 | ||
| 2023-08-15 | Naos Yaron Sr. VP, Operations | Grant or award | +187,344 | 200,817 | ||
| 2023-01-03 | Schwartz Aharon Director | Purchase | +110,000 | $1.42 | $156K | 174,000 |
| 2022-09-07 | Ben Zvi Shmuel Director | Grant or award · Stock Options (Right to Buy) | +10,000 | 10,000 | ||
| 2022-09-07 | Naos Yaron Sr. VP, Operations | Grant or award · Stock Options (Right to Buy) | +340,000 | 340,000 | ||
| 2022-09-07 | Hayon Yael VP, Research & Development | Grant or award · Stock Options (Right to Buy) | +250,000 | 250,000 |
Page 3 of 7 · 139 trades